Home > Information > BioSpotlight

BioSpotlight

2025-09-04

Understanding MERS-CoV: Structure, Pathogenesis, and Research Tools

This article explores Middle East Respiratory Syndrome Coronavirus (MERS-CoV), a high-fatality pathogen first identified in 2012, focusing on its structure, pathogenesis, and vaccine development challenges. It highlights the virus’s spike protein and DPP4 receptor interaction, with recent Nature findings revealing a MERS-CoV-like mink coronavirus using ACE2, underscoring zoonotic risks (Wang et al., 2025). The article details immune responses, including IL-6, TNFα, IFNγ, and CRP-driven cytokine storms, and discusses vaccine hurdles like antibody-dependent enhancement. abinScience’s recombinant proteins and antibodies are presented as essential tools for virology and immunology research, empowering studies on MERS-CoV and related coronaviruses.
2025-07-23

Chikungunya Virus in 2025: A Global Health Threat and the Role of Innovative Research

Discover the Chikungunya virus (CHIKV) structure, key proteins, and pathogenesis, with insights from the 2025 Foshan outbreak and global epidemiology. Learn about WHO’s warnings on CHIKV epidemic risks and explore abinScience’s advanced research tools, including recombinant proteins and antibodies, designed to support vaccine and antiviral development for this mosquito-borne disease.
2025-07-07

Combating Mosquito-Borne Diseases: Research Tools and Insights

Uncover the science behind mosquito-borne diseases like Chikungunya’s crippling joint pain, Dengue’s complex serotypes, West Nile’s neurological risks, Yellow Fever’s historic threat, Zika’s congenital dangers, and Japanese Encephalitis’s brain inflammation. Learn about the challenges of controlling these viruses and explore cutting-edge lab tools for diagnostics, vaccine development, and research. abinScience offers specialized antibodies and recombinant proteins to target viral proteins, empowering scientists to fight these global health threats effectively.
2025-05-22

COVID-19 Resurgence in 2025: Omicron NB.1.8.1 Drives Surge with Enhanced Immune Escape

Since April 2025, China has faced a resurgence of COVID-19, with positivity rates in outpatient and inpatient settings rising sharply from 7.5% to 16.2% and 3.3% to 6.3%, respectively. Southern provinces report higher infection rates than the north, with the Omicron NB.1.8.1 variant driving the surge due to its enhanced immune escape capabilities. Symptoms remain mild, including sore throat, low-grade fever, and cough. The pandemic is expected to peak in late May and subside by late June. abinScience offers high-quality SARS-CoV-2-related proteins and antibodies to support cutting-edge virology research.
2025-04-25

InVivoMAb™ Plus: Precision In Vivo Antibodies for Animal Models by abinScience

The abinScience InVivoMAb™ Plus series offers over 400 high-quality in vivo antibodies, validated for purity, specificity, and functionality, ideal for research in cancer, autoimmune diseases, and infectious diseases. This page details the activity validation experiments and ELISA tests of anti-PD-1 and anti-PD-L1 antibodies in mouse models (B16-F10 and CT26), demonstrating significant tumor suppression and antigen-binding capabilities. The product list includes a range of antibodies and isotype controls designed for immune regulation and tumor immunotherapy, supported by batch stability and traceability.
2025-07-30

Understanding Hepatitis C Virus: Structure, Pathogenesis, Vaccine Research & abinScience Tools

Discover the biology, structure, and pathogenesis of Hepatitis C Virus (HCV), including its virion structure and immune evasion strategies. Explore the latest advances in HCV vaccine development and effective tools from abinScience, such as recombinant proteins and antibodies, to support antiviral research. Updated July 30, 2025, this resource offers insights into DAA therapy and vertical transmission challenges.
2025-05-07

Science Discovery: The Role of Erythropoietin (EPO) in Tumor Immune Evasion

Recent research has uncovered a critical role for erythropoietin (EPO) in tumor immune evasion. Tumor cells secrete EPO, which, through the EPOR signaling pathway, suppresses the immune function of macrophages, aiding tumors in escaping immune surveillance. Blocking the EPO/EPOR signaling enhances the efficacy of PD-1 immunotherapy, offering a novel strategy for cancer treatment.
2025-08-13

Tuberculosis Research and Scientific Applications in 2025: Advances in Diagnosis, Treatment, and Vaccines

This schematic illustration highlights four key research areas in tuberculosis (TB) studies: ESAT-6/CFP-10 as core antigens for immunodiagnostic platforms (IGRA, ELISPOT), HspX as a biomarker for latent infection and stress response, KatG and InhA as primary targets for drug resistance mechanism analysis, and Ag85 series antigens for vaccine target validation. Designed for scientific publications, this figure supports research in TB diagnostics, immune mechanisms, and drug resistance studies.
2025-09-05

Cholera Outbreak 2025: Understanding Vibrio cholerae and Advances in Research

The World Health Organization reports over 400,000 cholera cases across 31 countries by mid-August 2025, with nearly 5,000 deaths, highlighting the disease's persistent global threat. Caused by Vibrio cholerae, cholera spreads through contaminated water and food, leading to severe dehydration and death if untreated. This article explores the bacterium’s structure, virulence factors like cholera toxin, pathogenesis, vaccine progress, and public health significance. It also highlights abinScience’s role in providing antibodies and recombinant proteins to support cholera research, emphasizing the need for continued scientific and social efforts to combat this deadly disease.
2025-08-29

Microglia and GZMK+ CD8+ T Cells: A Protective Axis Against Tau Pathology in Neurodegenerative Diseases

A Nature Immunology study utilizing P301S Tau mice reveals a critical interaction between GZMK+ CD8+ T cells and microglia in limiting the spread of phosphorylated Tau (pTau) and slowing neurodegeneration. High-dimensional flow cytometry, transcriptomics, and immunohistochemistry demonstrate that activated microglia and clonally expanded GZMK+ CD8+ T cells form a disease-associated immune ecosystem, with 76% of CD8+ T cells directly contacting microglia. Depletion of CD8+ T cells accelerates pTau spread and neuronal damage, while immune checkpoint molecules like PD-1/TIGIT regulate this protective axis. These findings highlight a novel immunotherapeutic target for tauopathies, including Alzheimer’s disease.
2025-08-27

WHO Reports Circulating Vaccine-Derived Poliovirus Type 1 Outbreak in Israel

In August 2025, the World Health Organization (WHO) reported nine circulating vaccine-derived poliovirus type 1 (cVDPV1) isolates from environmental samples in Jerusalem and central Israel. Although no paralytic cases have been detected, WHO classified the event as ongoing community transmission under the Public Health Emergency of International Concern (PHEIC). Poliovirus remains a global threat due to its potential to cause paralysis and death, especially in children. Israel’s outbreak underscores the importance of maintaining high, uniform vaccination coverage with IPV and nOPV to prevent resurgence and advance toward eradication.
2025-08-20

Targeting Microglial Cx43 Hemichannels: A Novel Approach to Alleviate Alzheimer’s Disease Pathology

This study identifies microglial Connexin43 (Cx43) hemichannels as a key target in Alzheimer’s disease (AD). Elevated Cx43 expression in AD patients correlates with disease progression. Knocking out microglial Cx43 in APP/PS1 mice increased compact plaques, reduced neuronal damage and oxidative stress, and improved cognition without changing plaque numbers. A selective Cx43 inhibitor, TAT-Cx43@LNPs, delivered via lipid nanoparticles, suppressed hemichannel activity, shifted microglia to a neuroprotective state, and alleviated AD pathology. Early intervention delayed disease progression, highlighting Cx43’s clinical potential.

Get a free quote